WO2002004610A2 - Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv - Google Patents

Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv Download PDF

Info

Publication number
WO2002004610A2
WO2002004610A2 PCT/EP2001/007730 EP0107730W WO0204610A2 WO 2002004610 A2 WO2002004610 A2 WO 2002004610A2 EP 0107730 W EP0107730 W EP 0107730W WO 0204610 A2 WO0204610 A2 WO 0204610A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptidase
dipeptidyl
enzyme
polypeptide
polynucleotide
Prior art date
Application number
PCT/EP2001/007730
Other languages
English (en)
Other versions
WO2002004610A3 (fr
Inventor
Yonghong Xiao
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Priority to AU2001269123A priority Critical patent/AU2001269123A1/en
Publication of WO2002004610A2 publication Critical patent/WO2002004610A2/fr
Publication of WO2002004610A3 publication Critical patent/WO2002004610A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to the area of regulation of human dipeptidyl-peptidase IV-like enzyme to provide therapeutic effects.
  • Dipeptidyl peptidase IV is a post-proline cleaving enzyme which will remove the di- peptides Xaa-Pro (Xaa is any amino acid) from the N-terminus of proteins or polypeptides.
  • Dipeptidyl peptidase IV has been found in a variety of mammalian cells and tissues including kidney, placenta, blood plasma, and neurological tissues. Dipeptidyl peptidase IV has been implicated as being involved in or associated with a number of conditions and diseases, including peripheral and central nervous system disorders including pain and neurodegenerative diseases and tumor angiogenesis.
  • dipeptidyl peptidase IV activity has been found to be higher in astrocytomas, gliomas, and immature human central nervous system tissue when compared to dipeptidyl peptidase IV activity in normal, adult human brain, suggesting that dipeptidyl peptidase IV may play a role in the development of the central nervous system as well as the development of neurodegenerative tumors (1, 2, 3).
  • the neurotransmitter neuropeptide Y of sympathetic neurons is converted by dipeptidyl peptidase IV activity into a form that serves as an angiogenic agonist (4). Dipeptidyl peptidase IV may therefore participate in the development of tumors in sympathetic nerves.
  • dipeptidyl peptidase IV activity contributes to the conversion of neuropeptides that are involved in neurodegenerative conditions (5). Regulation of dipeptidyl peptidase IV activity may prove critical for treating neuropeptidyl activation the leads to angiogenesis or neurodegeneration. Thus, there is a need in the art for identifying new dipeptidyl peptidase IV enzymes and methods of regulating their activities.
  • One embodiment of the invention is a dipeptidyl-peptidase IV-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 55% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ LO NO: 8.
  • Yet another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a dipeptidyl-peptidase IV-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 55% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8.
  • a test compound which binds to the dipeptidyl-peptidase IV-like enzyme polypeptide is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • the agent can work by decreasing the activity of the dipeptidyl-peptidase IV-like enzyme.
  • Another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a polynucleotide encoding a dipeptidyl-peptidase IV-like enzyme polypeptide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ LD NO: 7; and the nucleotide sequence shown in SEQ LD NO: 7.
  • a test compound which binds to the polynucleotide is identified as a potential agent for decreasing extracellular matrix degradation.
  • the agent can work by decreasing the amount of the dipeptidyl-peptidase IV-like enzyme through interacting with the dipeptidyl- peptidase IV-like enzyme mRNA.
  • Another embodiment of the invention is a method of screening for agents which regulate extracellular matrix degradation.
  • a test compound is contacted with a dipeptidyl-peptidase IV-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are at least about 55% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8.
  • a dipeptidyl-peptidase IV-like enzyme activity of the polypeptid is detectedr-A- est- compound which increases dipeptidyl-peptidase IV-like enzyme activity of the polypeptide relative to dipeptidyl-peptidase IV-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for increasing extracellular matrix degradation.
  • a test compound which decreases dipeptidyl-peptidase IV-like enzyme activity of the polypeptide relative to dipeptidyl-peptidase IV-like enzyme activity in the absence of the test compound is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • Even another embodiment of the invention is a method of screening for agents which decrease extracellular matrix degradation.
  • a test compound is contacted with a di- peptidyl-peptidase IV-like enzyme product of a polynucleotide which comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ LD NO: 7; and the nucleotide sequence shown in SEQ LD NO: 7.
  • a test compound which binds to the dipeptidyl-peptidase IV-like enzyme product is thereby identified as a potential agent for decreasing extracellular matrix degradation.
  • Still another embodiment of the invention is a method of reducing extracellular matrix degradation.
  • a cell is contacted with a reagent which specifically binds to a polynucleotide encoding a dipeptidyl-peptidase TV-like enzyme polypeptide or the product encoded by the polynucleotide, wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of: nucleotide sequences which are at least about 50% identical to the nucleotide sequence shown in SEQ ID NO: 7; and the nucleotide sequence shown in SEQ ID NO: 7.
  • Dipeptidyl-peptidase IV-like enzyme aetwity-in-th ⁇ cell4s thereby decreased.
  • the invention thus provides a human dipeptidyl-peptidase TV-like enzyme which can be used to identify test compounds which may act, for example, as agonists or antagonists at the enzyme's active site.
  • Human dipeptidyl-peptidase IV-like enzyme and fragments thereof also are useful in raising specific antibodies which can block the enzyme and effectively reduce its activity.
  • Fig. 1 shows the DNA-sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO: 1).
  • Fig. 2 shows the DNA-sequence encoding a dipeptidyl-peptidase TV-like enzyme polypeptide (SEQ LD NO:2).
  • Fig. 3 shows the DNA-sequence encoding a dipeptidyl-peptidase TV-like enzyme polypeptide (SEQ LD NO: 3).
  • Fig. 4 shows the DNA-sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO: 4).
  • FIG. 5 shows the DNA-sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO: 5).
  • Fig. 6 shows the DNA-sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ LD NO:6).
  • Fig. 7 shows the DNA-sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO: 7).
  • Fig. 8 shows the amino acid sequence deduced from the DNA-sequence of
  • Fig. 7 (SEQ LD NO: 8).
  • Fig. 9 shows the amino acid sequence of the protein identified with
  • Fig. 10 shows the amino acid sequence of Pfam Accession No. PF01738 hmm dienelactone hydrolase (DLH) family (SEQ ID NO: 10).
  • Fig. 11 shows the BLASTP alignment of dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO:8) with the protein identified by SwissProt
  • FIG. 12 shows the alignment of dipeptidyl-peptidase IV-like enzyme polypeptide (SEQ ID NO:8) with the Pfam Accession No. PF01738
  • Fig. 13 shows the abundance of human dipeptidyl-peptidase IV-like enzyme in phage libraries
  • Fig. 14 shows the gene expression of human dipeptidyl-peptidase TV-like enzyme in a human organ panel
  • Fig. 15 shows the gene expression of human dipeptidyl-peptidase TV-like enzyme in a human cardiovascular disease (CV) panel
  • Fig. 16 shows the gene expression of human dipeptidyl-peptidase TV-like enzyme in a CNS panel
  • the invention relates to an isolated polynucleotide encoding a dipeptidyl-peptidase IV-like enzyme polypeptide and being selected from the group consisting of: a) a polynucleotide encoding a dipeptidyl-peptidase IV-like enzyme polypeptide comprising an amino acid sequence selected from the group consisting of: amino acid sequences which are_at least about 55% identical to the amino acid sequence shown in SEQ ID NO: 8; and the amino acid sequence shown in SEQ ID NO: 8.
  • Human dipeptidyl-peptidase IV-like enzyme comprises the amino acid sequence shown in SEQ ID NO: 8, as encoded by the complement of the nucleotide sequence showjuiLSEQ ID NO:7.
  • SEQ LD NOS: 1-6 A number of ESTs are contained within the coding sequence of human dipeptidyl-peptidase TV-like enzyme (SEQ LD NOS: 1-6), indicating that the complement of SEQ LD NO:7 is expressed.
  • Human dipeptidyl-peptidase TV-like enzyme is 53% identical over a 114 amino acid overlap to the human protein identified by Swiss Prot Accession No. P42658 (SEQ LD NO:9) and annotated as dipeptidyl peptidase TV-like protein (FIG. 11). Human dipeptidyl-peptidase TV-like enzyme also contains many identities to amino acids present in a hidden Markov model (hmm) of dienelactone hydrolase domains derived from 42 dienelactone hydrolase-like sequences, as shown in FIG. 2.
  • hmm hidden Markov model
  • human dipeptidyl-peptidase TV-like enzyme of the invention is expected to be useful for the same purposes as previously identified dipeptidyl-peptidase IV enzymes.
  • human dipeptidyl-peptidase TV-like enzyme can be used in therapeutic methods to treat disorders such as tumors and neurodegenerative diseases.
  • Human dipeptidyl-peptidase IV-like enzyme also can be used to screen for human dipeptidyl-peptidase IV-like enzyme agonists and antagonists
  • Dipeptidyl-peptidase TV-like enzyme polypeptides comprise at least 14, 25, 50, 75, 100, 125, 150, 175, or 186 contiguous amino acids selected from the amino --acM*-sequenee shown tt-SEQ-LD NO:8 or a biologically active variant thereof, as defined below.
  • a dipeptidyl-peptidase IV-like enzyme polypeptide of the invention therefore can be a portion of a dipeptidyl-peptidase IV-like enzyme, a full-length dipeptidyl-peptidase IV-like enzyme, or a fusion protein comprising all or a portion of a dipeptidyl-peptidase IV-like enzyme.
  • Dipeptidyl-peptidase IV-like enzyme polypeptide variants which are biologically active, i.e., retain a dipeptidyl-peptidase IV-like activity, also are dipeptidyl-peptidase IV-like enzyme ⁇ . polypeptides.
  • naturally or non-naturally occurring dipeptidyl-peptidase IV-like enzyme polypeptide variants have amino acid sequences which are at least about 55, 60, 65, or 70, preferably about 75, 80, 85, 90, 96, 96, or 98% identical to the amino acid sequence shown in SEQ LD NO: 8 or a fragment thereof. Percent identity between a putative dipeptidyl-peptidase TV-like enzyme polypeptide variant and an amino acid sequence of SEQ ID NO: 8 is determined using the Blast2 alignment program (Blosum62, Expect 10, standard genetic codes).
  • Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions.
  • Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.
  • Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a dipeptidyl-peptidase IV-like enzyme polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active dipeptidyl-peptidase TV-like enzyme polypeptide can readily be determined by assaying for dipeptidyl-peptidase IV-like activity, as described for example, in the specific Examples, below.
  • Fusion proteins are useful for generating antibodies against dipeptidyl-peptidase IV-like enzyme polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a dipeptidyl-peptidase IV-like enzyme polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.
  • a dipeptidyl-peptidase TV-like enzyme polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond.
  • the first polypeptide segment can comprise at least 14, 25, 50, 75, 100, 125, 150, or 175 contiguous amino acids of SEQ ID NO:8 or of a biologically active variant, such as those described above.
  • the first polypeptide segment also can comprise full-length dipeptidyl-peptidase IV-like enzyme protein.
  • the second polypeptide segment can be a full-length protein or a protein fragment.
  • Proteins commonly used in fusion protein construction include ⁇ -galactosidase, ⁇ -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT).
  • epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
  • fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions.
  • MBP maltose binding protein
  • S-tag S-tag
  • GAL4 DNA binding domain fusions GAL4 DNA binding domain fusions
  • HSV herpes simplex virus
  • a fusion protein also can be engineered to contain a-cteavage ⁇ ite- located between the dipeptidyl-peptidase IV-like enzyme polypeptide-encoding sequence and the heterologous protein sequence, so that the dipeptidyl-peptidase TV-like enzyme polypeptide can be cleaved and purified away from the heterologous moiety.
  • a fusion protein can be synthesized chemically, as is known in the art.
  • a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology.
  • Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from the complement of SEQ ID NO:7 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art.
  • kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).
  • Species homologs of human dipeptidyl-peptidase IV-like enzyme polypeptide can be obtained using dipeptidyl-peptidase TV-like enzyme polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologs of dipeptidyl-peptidase IV-like enzyme polypeptide, and expressing the cDNAs as is known in the art.
  • a dipeptidyl-peptidase IV-like enzyme polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a dipeptidyl-peptidase IV-like enzyme polypeptide.
  • the complement of a coding sequence for human dipeptidyl-peptidase IV-like enzyme is shown in SEQ ID NO:7.
  • nucleotide sequences encoding human dipeptidyl-peptidase TV-like enzyme polypeptides as well as homologous nucleotide sequences which are at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, or 98% identical to the nucleotide sequence shown in SEQ ID NO:8 also are dipeptidyl-peptidase TV-like enzyme polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.
  • cDNA Complementary DNA (cDNA) molecules, species homologs, and variants of dipeptidyl-peptidase FV-like enzyme polynucleotides which encode biologically active dipeptidyl-peptidase TV-like enzyme polypeptides also are dipeptidyl-peptidase TV-like enzyme polynucleotides.
  • Variants and homologs of the dipeptidyl-peptidase TV-like enzyme polynucleotides described above also are dipeptidyl-peptidase TV-like enzyme polynucleotides.
  • homologous dipeptidyl-peptidase TV-like enzyme polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known dipeptidyl-peptidase TV-like polynucleotides under stringent conditions, as is known in the art.
  • homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous nucleic acid strands contain 15-25% basepair mismatches, even more preferably 5- 15%) basepair mismatches.
  • Species homologs of the dipeptidyl-peptidase IV-like enzyme polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast.
  • Human variants of dipeptidyl-peptidase TV-like enzyme polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T m of a double-stranded DNA decreases by 1-1.5 °C with every 1% decrease in homology (Bonner et al, J. Mol. Biol. 81, 123 (1973).
  • Variants of human dipeptidyl-peptidase IV-like enzyme polynucleotides or dipeptidyl-peptidase TV-like enzyme polynucleotides of other species can therefore be identified by hybridizing a putative homologous dipeptidyl-peptidase TV-like enzyme polynucleotide with a polynucleotide having a nucleotide sequence of SEQ ID NO:7 or the complement thereof to form a test hybrid.
  • the melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.
  • Nucleotide sequences which hybridize to dipeptidyl-peptidase TV-like enzyme polynucleotides or their complements following stringent hybridization and/or wash conditions also are dipeptidyl-peptidase TV-like enzyme polynucleotides.
  • Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook et al, MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed., 1989, at pages 9.50-9.51.
  • T m of a hybrid between a dipeptidyl-peptidase IV-like.enzyme polynucleotide having a nucleotide sequence shown in SEQ ID NO: 7 or the complement thereof and a polynucleotide sequence which is at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example 3 using the equation of Bolton and McCarthy, Proc. Natl Acad. Sci. U.S.A.
  • Stringent wash conditions include, for example, 4X SSC at 65 °C, or 50% formamide, 4X SSC at 42 °C, or 0.5X SSC, 0.1% SDS at 65 °C.
  • Highly stringent wash conditions include, for example, 0.2X SSC at 65 °C.
  • a dipeptidyl-peptidase TV-like enzyme polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids.
  • Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated dipeptidyl-peptidase TV-like enzyme polynucleotides.
  • restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises dipeptidyl-peptidase TV-like enzyme nucleotide sequences.
  • Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.
  • Dipeptidyl-peptidase TV-like enzyme cDNA molecules can be made with standard molecular biology techniques, using dipeptidyl-peptidase TV-like enzyme mRNA as a template.
  • Dipeptidyl-peptidase IV-like enzyme cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook et al. (1989).
  • An amplification technique, such as PCR can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or cDNA as a template.
  • dipeptidyl-peptidase TV-like enzyme polynucleotides can be synthesized using synthetic chemistry techniques to synthesize dipeptidyl-peptidase TV-like enzyme polynucleotides.
  • the degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a dipeptidyl-peptidase TV-like enzyme polypeptide having, for example, an amino acid sequence shown in SEQ ID NO: 8 or a biologically active variant thereof.
  • restriction site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, PCR Methods Applic. 2, 318322, 1993). Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.
  • Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region (Triglia et al, Nucleic Acids Res. 16, 8186, 1988).
  • Primers can be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences Inc., Madison, Minn.), to be 2230 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72 °C.
  • the method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.
  • capture PCR involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom et al, PCR Methods Applic. 1, 111119, 1991).
  • multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.
  • Randomly-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA.
  • capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera.
  • Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled.
  • Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.
  • Dipeptidyl-peptidase TV-like enzyme polypeptides can be obtained, for example, by purification from human cells, by expression of dipeptidyl-peptidase TV-like enzyme polynucleotides, or by direct chemical synthesis.
  • Dipeptidyl-peptidase IV-like enzyme polypeptides can be purified from any cell wlriclrexpresses the enzyme, including host cells which have been transfected with dipeptidyl-peptidase TV-like enzyme expression constructs. Brain and multiple sclerosis lesions provide especially useful sources of dipeptidyl-peptidase IV-like enzyme polypeptides.
  • a purified dipeptidyl-peptidase TV-like enzyme polypeptide is separated from other compounds which normally associate with the dipeptidyl-peptidase IV-like enzyme polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art.
  • Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis.
  • a preparation of purified dipeptidyl-peptidase IV-like enzyme polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.
  • the polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
  • Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding dipeptidyl-peptidase IV-like enzyme polypeptides and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et al. (1989) and in Ausubel et al, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1989.
  • a variety of expression vector/host systems can be utilized to contain and express sequences encoding a dipeptidyl-peptidase TV-like enzyme polypeptide.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus " expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
  • yeast transformed with yeast expression vectors insect cell systems infected with virus " expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic
  • control elements or regulatory sequences are those nontranslated regions of the vector enhancers, promoters, 5' and 3' untranslated regions which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORTl plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells.
  • Promoters or enhancers derived from the genomes of plant cells e.g., heat shock, RUBISCO, and storage protein genes
  • plant viruses e.g., viral promoters or leader sequences
  • promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a dipeptidyl-peptidase TV-like enzyme polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.
  • a number of expression vectors can be selected depending upon the use intended for the dipeptidyl-peptidase IV-like enzyme polypeptide. For example, when a large quantity of a dipeptidyl-peptidase TV-like enzyme polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used.
  • vectors include, but are not limited to, multifunctional E. coli cloning and expression vectors such as BLUESCRIPT (Stratagene).
  • a sequence encoding the dipeptidyl-peptidase IV-like enzyme polypeptide can be ligated into the vector in frame with sequences for the amino terminal Met and the subsequent-7-r-esidues of ⁇ -galactosidase so that a hybrid protein is produced.
  • pLN vectors Van Heeke & Schuster, J Biol. Chem. 264, 55035509, 1989
  • pGEX vectors Promega, Madison, Wis.
  • GST glutathione S-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
  • Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
  • yeast Saccharomyces cerevisiae a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used.
  • constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH.
  • sequences encoding dipeptidyl-peptidase IV-like enzyme polypeptides can be driven by any of a number of promoters.
  • viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV (Takamatsu, EMBO J. 6, 307311, 1987).
  • plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used (Coruzzi et al, EMBO J. 3, 16711680, 1984; Broglie et al, Science 224, 838843, 1984; Winter et al, Results Probl Cell Differ. 17, 85105, 1991).
  • constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection.
  • pathogen-mediated transfection Such techniques are described in a number of generally available reviews (e.g., Hobbs or Murray, in MCGRAW HILL YEARBOOK OF SCIENCE AND TECHNOLOGY, McGraw Hill, New York, N.Y., pp. 191196, 1992).
  • An insect system also can be used to express a dipeptidyl-peptidase IV-like enzyme polypeptide.
  • Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
  • Sequences encoding dipeptidyl-peptidase TV-like enzyme polypeptides can be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of dipeptidyl-peptidase TV-like enzyme polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein.
  • the recombinant viruses can then be used to infect S. frugiperda cells or Trichoplusia larvae in which dipeptidyl-peptidase IV-like enzyme polypeptides can be expressed (Engelhard et al, Proc. Nat. Acad. Sci. 91, 32243227, 1994).
  • Mammalian Expression Systems Mammalian Expression Systems
  • a number of viral based expression systems can be used to express dipeptidyl-peptidase IV-like enzyme polypeptides in mammalian host cells.
  • sequences encoding dipeptidyl-peptidase TV-like enzyme polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a nonessential El or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a dipeptidyl-peptidase IV-like enzyme polypeptide in infected host cells (Logan & Shenk, Proc. Natl. Acad. Sci. 81, 36553659, 1984).
  • transcription enhancers such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.
  • RSV Rous sarcoma virus
  • HACs Human artificial chromosomes
  • 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).
  • Specific initiation signals also can be used to achieve more efficient translation of sequences encoding dipeptidyl-peptidase IV-like enzyme polypeptides.
  • Such signals* include the ATG initiation codon and adjacent sequences.
  • sequences encoding a dipeptidyl-peptidase IV-like enzyme polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed.
  • exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert.
  • Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic.
  • the efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used (see Scharf et al., Results Probl Cell Differ. 20, 125162, 1994).
  • a host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed dipeptidyl-peptidase TV-like enzyme polypeptide in the desired fashion.
  • modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
  • Posttranslational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function.
  • Different host cells which have specific cellular machinery and characteristic mechanisms for Posttranslational activities e.g., CHO, HeLa, MDCK, HEK293, and WI38
  • ATCC American Type Culture Collection
  • Stable expression is preferred for long-term, high yield production of recombinant proteins.
  • cell lines which stably express dipeptidyl-peptidase TV-like enzyme polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on-the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 12 days in an enriched medium before they are switched to a selective medium.
  • the purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced dipeptidyl-peptidase TV-like enzyme sequences.
  • Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. See, for example, ANIMAL CELL CULTURE, R.I. Freshney, ed., 1986.
  • any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler et al., Cell 11, 22332, 1977) and adenine phosphoribosyltransferase (Lowy et al, Cell 22, 81723, 1980) genes which can be employed in tk ⁇ or aprf cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate (Wigler et al., Proc. Natl. Acad. Sci.
  • npt confers resistance to the aminoglycosides, neomycin and G418 (Colbere-Garapin et al, J. Mol. Biol. 150, 114, 1981), and als sn ⁇ pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murray, 1992, supra). Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. 85, 804751, 1988).
  • Visible markers such as anthocyanins, ⁇ -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to- quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes et al, Methods Mol. Biol. 55, 121131, 1995).
  • marker gene expression suggests that the dipeptidyl-peptidase IV-like enzyme polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a" dipeptidyl-peptidase IV-like enzyme polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode a dipeptidyl-peptidase IV-like enzyme polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a dipeptidyl-peptidase IV-like enzyme polypeptide under the control of a single promoter.
  • Expression of the marker gene in response to induction or selection usually indicates expression of the dipeptidyl-peptidase TV-like enzyme polynucleotide.
  • host cells which contain a dipeptidyl-peptidase TV-like enzyme polynucleotide and which express a dipeptidyl-peptidase TV-like enzyme polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of nucleic acid or protein.
  • the presence of a polynucleotide sequence encoding a dipeptidyl-peptidase TV-like enzyme polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a dipeptidyl-peptidase IV-like enzyme polypeptide.
  • Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a dipeptidyl-peptidase TV-like enzyme polypeptide to detect transformants which contain a dipeptidyl-peptidase IV-like enzyme polynucleotide.
  • a variety of protocols for detecting and measuring the expression of a dipeptidyl-peptidase IV-like enzyme polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).
  • ELISA enzyme linked immunosorbent assay
  • RIA radioimmunoassay
  • FACS fluorescence activated cell sorting
  • a tweezed, monoclonal-based immunoassay using-monoctonal antibodies reactive to two non-interfering epitopes on a dipeptidyl-peptidase IV-like enzyme polypeptide can be used, or a competitive binding assay can be employed.
  • labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays.
  • Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides -encoding dipeptidyl-peptidase IV-like enzyme polypeptides include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.
  • sequences encoding a dipeptidyl-peptidase TV-like enzyme polypeptide can be cloned into a vector for the production of an mRNA probe.
  • RNA probes are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
  • Host cells transformed with nucleotide sequences encoding a dipeptidyl-peptidase TV-like enzyme polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture.
  • the polypeptide produced by a transformed cell can be secreted or contained intracellularly depending on the sequence and/or the vector used.
  • expression vectors containing polynucleotides which encode dipeptidyl-peptidase IV-like enzyme polypeptides can be designed to contain signal sequences which direct secretion of soluble dipeptidyl-peptidase TV-like enzyme polypeptides through a prokaryotic or eukaryotic cell membrane or which direeHhe-membrane insertion of membrane-bound dipeptidyl-peptidase TV-like enzyme polypeptide.
  • purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity . purification system (Immunex Corp., Seattle, Wash.).
  • cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the dipeptidyl-peptidase IV-like enzyme polypeptide also can be used to facilitate purification.
  • One such expression vector provides for expression of a fusion protein containing a dipeptidyl-peptidase TV-like enzyme polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by LMAC (immobilized metal ion affinity chromatography, as described in Porath et al., Prot. Exp.
  • enterokinase cleavage site provides a means for purifying the dipeptidyl-peptidase IV-like enzyme polypeptide from the fusion protein.
  • Vectors which contain fusion proteins are disclosed in Kroll et al., DNA Cell Biol. 12, 441453, 1993.
  • Sequences encoding a dipeptidyl-peptidase IV-like enzyme polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers et al., Nuel Acids Res. Symp. Ser. 215223, 1980; Horn et al. Nuel Acids Res. Symp. Ser. 225232, 1980).
  • a dipeptidyl-peptidase TV-like enzyme polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid phase techniques (Merrifield, J. Am. Chem. Soc.
  • Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer).
  • fragments of dipeptidyl-peptidase IV-like enzyme polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.
  • the newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES, WH Freeman and Co., New York, N.Y., 1983).
  • the composition of a synthetic dipeptidyl-peptidase IV-like enzyme polypeptide can be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, supra). Additionally, any portion of the amino acid sequence of the dipeptidyl-peptidase TV-like enzyme polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.
  • codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.
  • nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter dipeptidyl-peptidase TV-like enzyme polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product.
  • DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences.
  • site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.
  • Antibody as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab') 2 , and Fv, which are capable of binding an epitope of a dipeptidyl-peptidase IV-like enzyme polypeptide.
  • Fab fragment antigen binding protein
  • F(ab') 2 fragment antigen binding protein
  • Fv fragment antigen binding protein
  • An antibody which specifically binds to an epitope of a dipeptidyl-peptidase TV-like enzyme polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
  • immunochemical assays such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art.
  • Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.
  • an antibody which specifically binds to a dipeptidyl-peptidase TV-like enzyme polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay.
  • antibodies which specifically bind to dipeptidyl-peptidase IV-like enzyme polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a dipeptidyl-peptidase IV-like enzyme polypeptide from solution.
  • Dipeptidyl-peptidase IV-like enzyme polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies.
  • a dipeptidyl-peptidase IV-like enzyme polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin.
  • a carrier protein such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin.
  • various adjuvants can be used to increase the immunological response.
  • adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g.
  • BCG Bacilli Calmette-Gueri ⁇
  • Corynebacterium parvum are especially useful.
  • Monoclonal antibodies which specifically bind to a dipeptidyl-peptidase TV-like enzyme polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human Bell hybridoma technique, and the EBV HYBRIDOMA technique (Kohler et al., Nature 256, 495497, 1985; Kozbor et al, J. Immunol. Methods 81, 3142, 1985; Cote et al, Proc. Natl. Acad. Sci. 80, 20262030, 1983; Cole et al, Mol. Cell Biol. 62, 109120, 1984).
  • chimeric antibodies the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison et al, Proc. Natl. Acad. Sci. 81, 68516855, 1984; Neuberger et al, Nature 312, 604608, 1984; Takeda et al, Nature 314, 452454, 1985).
  • Monoclonal and other antibodies also can be "humanized” to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues.
  • rodent ⁇ antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions.
  • humanized antibodies can be produced using recombinant methods, as described in GB2188638B.
  • Antibodies which specifically bind to a dipeptidyl-peptidase TV-like enzyme polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. 5,565,332.
  • single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to dipeptidyl-peptidase TV-like enzyme polypeptides.
  • Antibodies with related specificity, but of distinct idiotypic composition can be generated by chain shuffling from random combinatorial immunoglobin libraries (Burton, Proc. Natl Acad. Sci. 88, 1112023, 1991).
  • Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template (Thirion et al, 1996, Eur. J. Cancer Prev. 5, 507-11).
  • Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, 1997, Nat. Biotechnol 15, 159-63. Construction of bivalent, bispecific single-chain antibodies is taught in Mallender & Voss, 1994, J. Biol Chem. 269, 199-206.
  • a nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below.
  • single-chain antibodies can be produced directly using, for example, filamentous phage technology (Verhaar et al., 1995, Int. J. Cancer 61, 497-501; Nicholls et al, 1993, J. Immunol. Meth. 165, 81-91).
  • Antibodies which specifically bind to dipeptidyl-peptidase IV-like enzyme polypeptides also can be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi et al, Proc. Natl. Acad. Sci. 86, 38333837, 1989; Winter et al, Nature 349, 293299, 1991).
  • chimeric antibodies can be constructed as disclosed in WO 93/03151.
  • Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, also can be prepared.
  • Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a dipeptidyl-peptidase TV-like enzyme polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.
  • Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation.
  • an antisense oHgonucleotide is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used.
  • Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of dipeptidyl-peptidase TV-like enzyme gene products in the cell.
  • dipeptidyl-peptidase TV-like enzyme gene expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the dipeptidyl-peptidase IV-like enzyme gene. Oligonucleotides derived from the transcription initiation site, e.g., between positions 10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base pairing methodology.
  • Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons.
  • Therapeutic advances using triplex DNA have been described in the literature (e.g., Gee et al., in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Futura Publishing Co., Mt. Kisco, N.Y., 1994).
  • An antisense oHgonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.
  • Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a dipeptidyl-peptidase TV-like enzyme polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent dipeptidyl-peptidase IV-like enzyme nucleotides, can provide sufficient targeting specificity for dipeptidyl-peptidase TV-like enzyme mRNA.
  • each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length.
  • Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length.
  • One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oHgonucleotide and a particular dipeptidyl-peptidase IV-like enzyme polynucleotide sequence.
  • Antisense oligonucleotides can be modified without affecting their ability to hybridize to a dipeptidyl-peptidase IV-like enzyme polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule.
  • internucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose.
  • Modified bases and/or sugars such as arabinose instead of ribose, or a 3', substituted oHgonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oHgonucleotide.
  • modified oligonucleotides can be prepared by methods well known in the art. See, e.g., Agrawal et al., Trends Biotechnol 10, 152158, 1992; Uhlmann et al, Chem. Rev. 90, 543584, 1990; Uhlmann et al., Tetrahedron. Lett. 215, 35393542, 1987.
  • Ribozymes are RNA molecules with catalytic activity. See, e.g., Cech, Science 236, 15321539; 1987; Cech, Ann. Rev. Biochem. 59, 543568; 1990, Cech, Curr. Opin. Struct. Biol. 2, 605609; 1992, Couture & Stinchcomb, Trends Genet. 12, 510515, 1996. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff et al, U.S. Patent 5,641,673).
  • ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific-micieetide' sequences.
  • the coding sequence of a dipeptidyl-peptidase TV-like enzyme polynucleotide can be used to generate ribozymes which will specifically bind to mRNA transcribed from the dipeptidyl-peptidase IV-like enzyme polynucleotide.
  • Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art (see Haseloff et al. Nature 334, 585591, 1988).
  • the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region,- into the ribozyme.
  • the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target (see, for example, Gerlach et al, EP 321,201).
  • ribozyme cleavage sites within a dipeptidyl-peptidase IV-like enzyme RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate dipeptidyl-peptidase IV-like enzyme RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.
  • hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.
  • Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA c ⁇ struct into cells in which it is desired to decrease dipeptidyl-peptidase IV-like enzyme expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art.
  • a ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.
  • ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.
  • the invention provides assays for screening test compounds which bind to or modulate the activity of a dipeptidyl-peptidase TV-like enzyme polypeptide or a dipeptidyl-peptidase TV-like enzyme polynucleotide.
  • a test compound preferably binds to a dipeptidyl-peptidase IV-like enzyme polypeptide or polynucleotide. More preferably, a test compound decreases or increases dipeptidyl-peptidase TV-like activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.
  • Test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity.
  • the compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library-methods requiring deconvolution, the "one-bead one compound” library method, and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. See Lam, Anticancer Drug Des. 12, 145, 1997.
  • Test compounds can be screened for the ability to bind to dipeptidyl-peptidase IV-like enzyme polypeptides or polynucleotides or to affect dipeptidyl-peptidase IV-like enzyme activity or dipeptidyl-peptidase TV-like enzyme gene expression using high throughput screening.
  • high throughput screening many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened.
  • the most widely established techniques utilize 96-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 50 to 500 ⁇ l.
  • many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the 96- well format.
  • Free format assays or assays that have no physical barrier between samples, can be used.
  • an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme et al, Proc. Natl. Acad. Sci. U.S.A. 19, 161418 (1994).
  • the cells are placed under agarose in perri dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose.
  • the combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualized as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.
  • Chelsky "Strategies for Screening Combinatorial Libraries: Novel and Traditional Approaches," reported at the First Annual Conference of The Society for Biomolecular Screening in Philadelphia, Pa. (Nov. 710, 1995).
  • Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel.
  • beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV LIGHT. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.
  • test samples are placed in a porous matrix.
  • One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
  • a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support.
  • the test compound is preferably a small molecule which binds to and occupies, for example, the ATP/GTP binding site of the enzyme or the active site of the dipeptidyl-peptidase IV-like enzyme polypeptide, such that normal biological activity is prevented.
  • small molecules include, but are not limited to, small peptides or peptide like molecules.
  • either the test compound or the dipeptidyl-peptidase IV-like enzyme polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • a detectable label such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • Detection of a test compound which is bound to the dipeptidyl-peptidase TV-like enzyme polypeptide can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.
  • binding of a test compound to a dipeptidyl-peptidase IV-Hke enzyme polypeptide can be determined without labeling either of the interactants.
  • a microphysiometer can be used to detect binding of a test compound with a dipeptidyl-peptidase TV-like enzyme polypeptide.
  • a microphysiometer e.g., CytosensorTM
  • a microphysiometer is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a dipeptidyl-peptidase TV-like enzyme polypeptide (McConnell et al, Science 257, 19061912, 1992).
  • BIA Bimolecular Interaction Analysis
  • a dipeptidyl-peptidase TV-like enzyme polypeptide can be used as a "bait protein" in a two hybrid assay or three-hybrid assay (see, e.g., U.S. Patent 5,283,317; Zervos et al, Cell 72, 223232, 1993; Madura et al, J. Biol. Chem.
  • polynucleotide encoding a dipeptidyl-peptidase TV-like enzyme polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL4).
  • a DNA sequence that encodes an unidentified protein (“prey” or “sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey” proteins are able to interact in vivo to form an protein dependent complex, the DNA BINDING and activation domains of the transcription factor are brought into close proximity.
  • reporter gene e.g., LacZ
  • a reporter gene e.g., LacZ
  • Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the dipeptidyl-peptidase TV-like enzyme polypeptide.
  • either the dipeptidyl-peptidase IV-like enzyme polypeptide (or polynucleotide) or the test compound can be bound to a solid support.
  • suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads).
  • any method known in the art can be used to attach the dipeptidyl-peptidase IV-like enzyme polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide.) or.test compound and the solid support.
  • Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a dipeptidyl-peptidase IV-like enzyme polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.
  • the dipeptidyl-peptidase TV-like enzyme polypeptide is a fusion protein comprising a domain that allows the dipeptidyl-peptidase IV-like enzyme polypeptide to be bound to a solid support.
  • glutathione S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the nonadsorbed dipeptidyl-peptidase TV-like enzyme polypeptide; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH).
  • Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.
  • a dipeptidyl-peptidase IV-like enzyme polypeptide or polynucleotide
  • a test compound can be immobilized utilizing conjugation of biotin and strep tavidin.
  • Biotinylated dipeptidyl-peptidase IV-like enzyme polypeptides (or polynucleotides) or test compounds can be prepared from biotinNHS(Nhydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, 111.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical).
  • antibodies which specifically bind to a dipeptidyl-peptidase IV-like enzyme polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the ATP/GTP binding site or the active site of the dipeptidyl-peptidase IV-like enzyme polypeptide can be derivatized to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.
  • Methods for detecting such complexes include immunodetection of complexes using antibodies which specifically bind to the dipeptidyl-peptidase IV-like enzyme polypeptide or test compound, enzyme linked assays which rely on detecting an activity of the dipeptidyl-peptidase TV-like enzyme polypeptide, and SDS gel electrophoresis under non-reducing conditions.
  • Any cell which comprises a dipeptidyl-peptidase IV-like enzyme polypeptide or polynucleotide can be used in a cell-based assay system.
  • a dipeptidyl-peptidase IV-like enzyme polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a dipeptidyl-peptidase TV-like enzyme polypeptide or polynucleotide is determined as described above.
  • Test compounds can be tested for the ability— to- increase * or - decrease the dipeptidyl-peptidase IV activity of a human dipeptidyl-peptidase IV-like enzyme polypeptide.
  • Dipeptidyl-peptidase TV activity can be measured, for example, as described in U.S. Patent 5,601,986 (see Example 2).
  • Enzyme assays can be carried out after contacting either a purified dipeptidyl-peptidase IV-like enzyme polypeptide, a cell membrane preparation, or an intact cell with a test compound.
  • a test compound which decreases a transketolase activity of a dipeptidyl-peptidase IV-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for decreasing dipeptidyl-peptidase IV-like enzyme activity.
  • a test compound which increases a transketolase activity of a human dipeptidyl-peptidase TV-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% is identified as a potential therapeutic agent for increasing human dipeptidyl-peptidase IV-like enzyme activity.
  • test compounds which increase or decrease dipeptidyl-peptidase IV-like enzyme gene expression are identified.
  • a dipeptidyl-peptidase IV-like enzyme polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the dipeptidyl-peptidase TV-like enzyme polynucleotide is determined.
  • the level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of mRNA or polypeptide in the absence of the test compound.
  • the test compound can then be identified as a modulator of expression based on this comparison.
  • test compound when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression.
  • test compound when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.
  • the level of dipeptidyl-peptidase IV-like enzyme mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used.
  • the presence of polypeptide products of a dipeptidyl-peptidase IV-like enzyme polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry.
  • polypeptide synthesis can be determined in vivo, in a cell culture, or in an in vitro translation system by detecting incorporation of labeled amino acids into a dipeptidyl-peptidase IV-like enzyme polypeptide.
  • screening can be carried out either in a cell-free assay system or in an intact cell.
  • Any cell which expresses a dipeptidyl-peptidase TV-like enzyme polynucleotide can be used in a cell-based assay system.
  • the dipeptidyl-peptidase TV-like enzyme polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.
  • compositions of the invention can comprise, for example, a dipeptidyl-peptidase IV-like enzyme polypeptide, dipeptidyl-peptidase TV-like enzyme polynucleotide, ribozymes or antisense oligonucleotides, antibodies which specifically bind to a dipeptidyl-peptidase IV-like enzyme polypeptide, or mimetics, agonists, antagonists, or inhibitors of a dipeptidyl-peptidase TV-like enzyme polypeptide activity.
  • compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • agent such as stabilizing compound
  • the compositions can be administered to a patient alone, or in combination with other agents, drugs or-hormones.
  • compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means.
  • Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.
  • compositions for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxy- propylmethylcellulose, or sodium carboxymethylceUulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen.
  • disintegrating or solubilizing agents can be added, such as the cross linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
  • Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • suitable coatings such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.
  • Push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
  • the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.
  • compositions suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Non-lipid polycationic amino polymers also can be used for delivery.
  • the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • the pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts-tend- to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
  • the preferred preparation can be a lyophilized powder which can contain any or all of the following: 150 mM histidine, 0.1 %2% sucrose, and 27% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
  • compositions After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.
  • Cancer is a disease fundamentally caused by oncogenic cellular transformation. There are several hallmarks of transformed cells that distinguish them from their normal counterparts and underlie the pathophysiology of cancer. These include uncontrolled cellular proliferation, unresponsiveness to normal death inducing signals (immortalization), increased cellular motility and invasiveness, increased abiHty to recruit blood supply through induction of new blood vessel formation (angiogenesis), genetic instability, and dysregulated gene expression. Various combinations of these aberrant physiologies, along with the acquisition of drug resistance frequently lead to an intractable disease state in which organ failure and patient death ultimately ensue.
  • genomics driven molecular target identification has opened up the possibility of identifying new cancer specific targets for therapeutic intervention that will provide safer, more effective treatments for cancer patients.
  • newly discovered tumor associated genes and their products can be tested for their role(s) in disease and used as tools to discover and develop innovative therapies.
  • Genes playing important roles in any of the physiological processes outlined above can be characterized as cancer targets.
  • Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized in vitro for their biochemical properties and then used as tools in high throughput molecular screening programs to identify chemical modulators of their biochemical activities.
  • Agonists and/or antagonists of target protein activity can be identified in this manner and subsequently tested in cellular and in vivo disease models for anticancer activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.
  • the human dipeptidyl-peptidase TV-like gene provides a therapeutic target for preventing cancers and/or tumors associated with neurodegenerative diseases and nervous system tissues. Based on its immunoreactivity, the levels of dipeptidyl-peptidase IV enzyme are much higher in the immature central nervous system of fetuses and newborn children than in the adult human brain (3), indicating that dipeptidyl-peptidase IV is expressed in actively developing nervous tissue. However, the content of dipeptidyl-peptidase TV is higher in glioma and astrocytoma tissue compared to normal brain tissue (1), and is also abundant in an astrocytoma cell line (2).
  • dipeptidyl-peptidase TV activity is therefore a part of normal neural development
  • dipeptidyl-peptidase IV activity also is associated with the- abnormal growth of neural tissue in gliomas and astrocytomas. Suppression of dipeptidyl-peptidase IV-like activity may therefore suppress growth of neural tumors, such as those that occur in gliomas and astrocytomas.
  • Dipeptidyl-peptidase TV activity has further been indicated as contributing to angiogenesis associated with neural tissues.
  • the sympathetic neuro-cotransmitter neuropeptide Y has been evidenced to be angiogenic for human endothelial cells in vitro, as it promotes sprouting and adhesion of vessels, migration, proliferation, and capillary tube formation (4).
  • Neuropeptide Y has also been shown to be angiogenic in vivo in a murine assay for angiogenesis (4).
  • the angiogenic property of neuropeptide Y appears to be mediated by the Y2 receptor, which recognizes neuropeptide Y after the terminal amino acids Tyr-Pro have been cleaved by dipeptidyl-peptidase TV.
  • neuropeptide Y Based on the angiogenic properties of neuropeptide Y after cleavage by dipeptidyl-peptidase TV, neuropeptide Y has been implicated in angiogenesis that accompanies growth of neural tumors. Compounds directed against dipeptidyl-peptidase TV-like activity may therefore prove useful as therapeutics for inhibiting angiogenesis of neural tissue tumors. Neurodegenerative diseases, such as multiple sclerosis, also can be treated.
  • Central and peripheral nervous system disorders also can be treated, such as primary and secondary disorders after brain injury, disorders of mood, anxiety disorders, disorders of thought and volition, disorders of sleep and wakefulness, diseases of the motor unit, such as neurogenic and myopathic disorders, neurodegenerative disorders such as Alzheimer's and Parkinson's disease, and processes of peripheral and chronic pain.
  • Pain that is associated with CNS disorders also can be treated by regulating the activity of human dipeptidyl-peptidase IV-like enzyme. Pain which can be treated includes that associated with central nervous system disorders, such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation).
  • central nervous system disorders such as multiple sclerosis, spinal cord injury, sciatica, failed back surgery syndrome, traumatic brain injury, epilepsy, Parkinson's disease, post-stroke, and vascular lesions in the brain and spinal cord (e.g., infarct, hemorrhage, vascular malformation).
  • Non-central neuropathic pain includes that associated with post mastectomy pain, reflex sympathetic dystrophy (RSD), trigeminal neuralgiaradioculopathy, post-surgical pain, HIV/AIDS related pain, cancer pain, metabolic neuropathies (e.g., diabetic neuropathy, vasculitic neuropathy secondary to connective tissue disease), paraneoplastic polyneuropathy associated, for example, with carcinoma of lung, or leukemia, or lymphoma, or carcinoma of prostate, colon or stomach, trigeminal neuralgia, cranial neuralgias, and post-herpetic neuralgia. Pain associated with cancer and cancer treatment also can be treated, as can headache pain (for example, migraine with aura, migraine without aura, and other migraine disorders), episodic and chronic tension-type headache, tension-type like headache, cluster headache, and chronic paroxysmal hemicrania.
  • headache pain for example, migraine with aura, migraine without aura, and other migraine disorders
  • episodic and chronic tension-type headache tension-type like headache, cluster headache, and chronic par
  • This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model.
  • an agent identified as described herein e.g., a modulating agent, an antisense nucleic acid molecule, a specific antibody, ribozyme, or a dipeptidyl-peptidase TV-like enzyme polypeptide binding molecule
  • an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent.
  • this invention pertains to uses of novel agents identified by the above described screening assays for treatments as described herein.
  • a reagent which affects dipeptidyl-peptidase IV-like enzyme activity can be administered to a human cell, either in vitro or in vivo, to reduce dipeptidyl-peptidase IV-like enzyme activity.
  • the reagent preferably binds to an expression product of a human dipeptidyl-peptidase IV-like enzyme gene. If the expression product is a protein, the reagent is preferably an antibody.
  • an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.
  • the reagent is delivered using a liposome.
  • the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours.
  • a liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human.
  • the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.
  • a liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell.
  • the transfection efficiency of a liposome is about 0.5 ⁇ g of DNA per 16 nmole of liposome delivered to about 10 6 cells, more preferably about 1.0 ⁇ g of DNA per 16 nmole of liposome delivered to about 10 6 cells, and even more preferably about 2.0 ⁇ g of DNA per 16 nmol of liposome delivered to about 10 6 cells.
  • a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.
  • Suitable liposomes for use in the present invention include those liposomes standardly used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol.
  • a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.
  • a liposome with a reagent such as an antisense oHgonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151).
  • a reagent such as an antisense oHgonucleotide or ribozyme
  • a reagent such as an antisense oHgonucleotide or ribozyme
  • antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery.
  • Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol 11, 202-05 (1993); Chiou et al, GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al, J. Biol. Chem. 269, 542-46 (1994); Zenke et al, Proc. Natl. Acad. Sci. U A. 87, 3655-59 (1990); ⁇ u et al., J. Biol. Chem. 266, 338-42 (1991).
  • a therapeutically effective dose refers to that amount of active ingredient which increases or decreases dipeptidyl-peptidase TV-like enzyme activity relative to the dipeptidyl-peptidase IV-like enzyme activity which occurs in the absence of the therapeutically effective dose.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs.
  • the animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity e.g., ED 50 (the dose therapeutically effective in 50% of the population) and LD 0 (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals.
  • the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 50 /ED 5 o.
  • compositions which exhibit large therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use.
  • the dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect.
  • Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Long acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.
  • Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
  • polynucleotides encoding the antibody can be constructed and introduced into a cell either ex vivo or in vivo using well-established techniques including, but not limited to, transferrin-polycation-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, Hposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, "gene gun,” and DEAE- or calcium phosphate-mediated transfection.
  • Effective in vivo dosages of an antibody are in the range of about 5 ⁇ g to about 50 ⁇ g/kg, about 50 ⁇ g to about 5 mg/kg, about 100 ⁇ g to about 500 ⁇ g/kg of patient body weight, and about 200 to about 250 ⁇ g/kg of patient body weight.
  • effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 ⁇ g to about 2 mg, about 5 ⁇ g to about 500 ⁇ g, and about 20 ⁇ g to about 100 ⁇ g of DNA.
  • the reagent is preferably an antisense oHgonucleotide or a ribozyme.
  • Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.
  • a reagent reduces expression of a dipeptidyl-peptidase IV-like enzyme gene or the activity of a dipeptidyl-peptidase IV-like enzyme polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100%) relative to the absence of the reagent.
  • the effectiveness of the mechanism chosen to decrease the level of expression of a dipeptidyl-peptidase IV-like enzyme gene or the activity of a dipeptidyl-peptidase IV-like enzyme polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to dipeptidyl-peptidase TV-like enzyme-specific mRNA, quantitative RT-PCR, immunologic detection of a dipeptidyl-peptidase TV-like enzyme polypeptide, or measurement of dipeptidyl- peptidase TV-like enzyme activity.
  • any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents.
  • Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles.
  • the combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
  • any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans. Diagnostic Methods
  • Human dipeptidyl-peptidase TV-like enzyme also can be used in diagnostic assays for detecting diseases and abnormalities or susceptibility to diseases and abnormalities related to the presence of mutations in the nucleic acid sequences which encode the enzyme. For example, differences can be determined between the cDNA or genomic sequence encoding dipeptidyl-peptidase TV-like enzyme in individuals afflicted with a disease and in normal individuals. If a mutation is observed in some or all of the afflicted individuals but not in normal individuals, then the mutation is likely to be the causative agent of the disease.
  • Sequence differences between a reference gene and a gene having mutations can be revealed by the direct DNA sequencing method.
  • cloned DNA segments can be employed as probes to detect specific DNA segments.
  • the sensitivity of this method is greatly enhanced when combined with PCR.
  • a sequencing primer can be used with a double-stranded PCR product or a single stranded template molecule generated by a modified PCR.
  • the sequence determination is performed by conventional procedures using radiolabeled nucleotides or by automatic sequencing procedures using fluorescent tags.
  • DNA sequence differences can be carried out by detection of alteration in electrophoretic mobility of DNA fragments in gels with or without denaturing agents. Small sequence deletions and insertions can be visualized, for example, by high resolution gel electrophoresis. DNA fragments of different sequences can be distinguished on denaturing formamide gradient gels in which the mobilities of different DNA fragments are retarded in the gel at different positions according to their specific melting or partial melting temperatures (see, e.g., Myers et al., Science 230, 1242, 1985). Sequence changes at specific locations can also be revealed by nuclease protection assays, such as RNase and S 1 protection or the chemical cleavage method (e.g., Cotton et al, Proc. Natl.
  • the detection of a specific DNA sequence can be performed by methods such as hybridization, RNase protection, chemical cleavage, direct DNA sequencing or the use of restriction enzymes and Southern blotting of genomic DNA.
  • direct methods such as gel electrophoresis and DNA sequencing, mutations can also be detected by in situ analysis.
  • Altered levels of a dipeptidyl-peptidase TV-like enzyme also can be detected in various tissues.
  • Assays used to detect levels of the receptor polypeptides in a body sample, such as blood or a tissue biopsy, derived from a host are well known to those of skill in the art and include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays.
  • the polynucleotide of SEQ LD NO: 7 is inserted into the expression vector pCEV4 and the expression vector pCEV4-dipeptidyl-peptidase IV-like enzyme polypeptide obtained is transfected into human embryonic kidney 293 cells.
  • the dipeptidyl-peptidase TV-like enzyme activity is measured at 24 °C, by mixing 50 or 100 ⁇ l of cell extracts to 100 or 150 ⁇ l microliters of a reaction buffer containing 200 ⁇ M of chromogenic substrate, such as Gly-Pro-PNA (commercially available from Bachem, San Diego, Calif.) "* in 0.1 M Tris-HCl buffered Triton X-100 (0.1% v/v) at pH 7.0.
  • the reactions are incubated for 30 minutes, and optical density readings are taken at 405 nm. During the reaction time course, several optical density readings are taken at different time points.
  • Dipeptidyl-peptidase TV-like enzyme activity is expressed in nmol/min/ml based on the progression curve calculated from the concentration of hydrolyzed substrates. It is shown that SEQ ID NO: 8 has dipeptidyl-peptidase TV-like enzyme activity.
  • the Pichia pastoris expression vector pPICZB (Invitrogen, San Diego, CA) is used to produce large quantities of recombinant human dipeptidyl-peptidase IV-like polypeptides in yeast.
  • the dipeptidyl-peptidase TV-like enzyme-encoding DNA sequence is derived from the complement of SEQ ID NO:7.
  • the DNA sequence is modified by well known methods in such a way that it contains at its 5' end an initiation codon and at its 3' end an enterokinase cleavage site, a His6 reporter tag and a termination codon.
  • the yeast is cultivated under usual conditions in 5 liter shake flasks and the recombinantly produced protein isolated from the culture by affinity chromatography (NiNTAResin) in the presence of 8 M urea.
  • the bound polypeptide is eluted with buffer, pH 3.5, and neutralized. Separation of the polypeptide from the His6 reporter tag is accomplished by site-specific proteolysis using enterokinase (Invitrogen, San Diego, CA) according to manufacturer's instructions. Purified human dipeptidyl- peptidase IV-like enzyme polypeptide is obtained.
  • Dipeptidyl-peptidase TV-like activity can be assayed using cellular extracts from human cell lines, such as the astrocytoma cell lines CRL-1718 or HTB-15. Test compounds from a small molecule library can be assayed for their ability to regulate dipeptidyl-peptidase IV-like activity by contacting CRL-1718 or HTB-15 cell line extracts with the test compounds. Control extracts, in the absence of a test compound, are also assayed. Dipeptidyl-peptidase IV-like activity can be assayed using a substrate which reacts with dipeptidyl-peptidase TV to form a detectable product, as described in U.S. Patent 5,601,986.
  • Suitable enzyme substrates include, but are not limited to, dipeptide substrates such as Xaa-pro-para-nitro-analide (Xaa-Pro-PNA) or Xaa-Pro-coumarin.
  • the variable amino acid, Xaa can be any naturally occurring or synthetic amino acid.
  • An exemplary dipeptide substrate is Gly-Pro-para-nitro-analide (Gly-Pro-PNA).
  • Gly-Pro-PNA Gly-Pro-para-nitro-analide
  • the substrate has no absorbance; however, if the dipeptide substrate is cleaved (after the Pro) due to the presence of dipeptidyl-peptidase IV, the formation of a reaction product can be visualized spectrophotometrically, as a yellow-green color is produced.
  • Other substrates, such as Xaa-Pro-coumarin can be visualized spectrofluorometrically as a fluorescent emission is produced by the reaction.
  • Dipeptidyl-peptidase TV Assays embodying such reagents and reactions can be performed in any suitable reaction vessel, for example, a test tube or well of a microtiter plate. Enzyme activities typically are measured at 24 °C, by mixing 50 or 100 ⁇ l of enzyme sample to 100 or 150 ⁇ l microliters of a reaction buffer containing 200 ⁇ M of chromogenic substrate, such as Gly-Pro-PNA (commercially available from Bachem, San Diego, Calif.) in 0.1 M Tris-HCl buffered Triton X-100 (0.1% v/v) at pH 7.0. The reactions are incubated for 30 minutes, and optical density readings are taken at 405 nm. During the reaction time course, several optical density readings are taken at different time points. Dipeptidyl-peptidase TV-like enzyme activity is expressed in nmol/min/ml based on the progression curve calculated from the concentration of hydrolyzed substrates.
  • chromogenic substrate such as Gly-
  • a test compound which decreases dipeptidyl-peptidase IV-like activity of an enzyme relative to the control preparation by at least 20% is identified as a dipeptidyl-peptidase IV-like enzyme inhibitor.
  • Dipeptidyl-peptidase IV-like enzyme polypeptides comprising a glutathione-S-transferase protein and absorbed onto glutathione-derivatized wells of 96-well microtiter plates are contacted with test compounds from a small molecule library at pH 7.0 in a physiological buffer solution.
  • Dipeptidyl-peptidase IV-like enzyme polypeptides comprise the amino acid sequence shown in SEQ ID NO:8.
  • the test compounds comprise a fluorescent tag. The samples are incubated for 5 minutes to one hour. Control samples are incubated in the absence of a test compound.
  • the buffer solution containing the test compounds is washed from the wells. Binding of a test compound to a dipeptidyl-peptidase IV-like enzyme polypeptide is detected by fluorescence measurements of the contents of the wells.
  • a test compound which increases the fluorescence in a well by at least 15% relative to fluorescence of a well in which a test compound is not incubated is identified as a compound which binds to a dipeptidyl-peptidase TV-like enzyme polypeptide.
  • test compound is administered to a culture of human cells transfected with a dipeptidyl-peptidase IV-like enzyme expression construct and incubated at 37 °C for 10 to 45 minutes.
  • a culture of the same type of cells which have not been transfected is incubated for the same time without the test compound to provide a negative control.
  • RNA is isolated from the two cultures as described in Chirgwin et al., Biochem. 18, 5294-99, 1979).
  • Northern blots are prepared using 20 to 30 Fg total RNA and hybridized with a 32 P-labeled dipeptidyl-peptidase TV-like enzyme-specific probe at 65 ° C in Express-hyb (CLONTECH).
  • the probe comprises at least 11 contiguous nucleotides selected from SEQ ID NO:7.
  • a test compound which decreases the dipeptidyl-peptidase TV-like enzyme-specific signal relative to the signal obtained in the absence of the test compound is identified as an inhibitor of dipeptidyl-peptidase IV-like enzyme gene expression.
  • oligonucleotides comprising at least 11 contiguous nucleotides selected from SEQ LD NO: 7 is performed on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (Uhlmann et al., Chem. Rev. 90, 534-83, 1990). Following assembly and deprotection, oligonucleotides are ethanol-precipitated twice, dried, and suspended in phosphate buffered saline (PBS) at the desired concentration. Purity of these oligonucleotides is tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oHgonucleotide preparation are determined using the Limulus Amebocyte Assay (Bang, Biol. Bull. (Woods Hole, Mass.) 105, 361362, 1953).
  • the antisense oligonucleotides are administered to a patient with multiple sclerosis.
  • the severity of the patient's multiple sclerosis is decreased.
  • PCR reaction 0.5 ⁇ l of each library purchased sample were used as template in PCR analysis regardless the title (phage/ml) for non quantitative expression analysis.
  • a positive control PCR reaction was performed with about 20 ng of human genomic DNA as template and a negative control was performed with no template.
  • Primer A 5 '-GGATGCCATCTAAGGAAGAAAGCAC-3 '
  • Primer B 5 '-CAGAACAAACAGGGGGATAACAGAAG-3 '
  • Amplification products were analysed by electrophoresis on 2% agarose (SeaKem LE agarose, FMC bioproducts) gel in IXTAE running buffer following standard procedure, as described by Maniatis et al.
  • PCR amplification products of the expected size were detectable some of the phage libraries.
  • Quantitative expression profiling was performed by the form of quantitative PCR analysis called "kinetic analysis” firstly described in Higuchi et al., 1992 and Higuchi et al., 1993. The principle is that at any given cycle within the exponential phase of PCR, the amount of product is proportional to the initial number of template copies.
  • the probe is cleaved by the 5 '-3' endonuclease activity of Taq DNA polymerase and a fluorescent dye released in the medium (Holland et al.). Since the fluorescence emission will increase in direct proportion to the amount of the specific amplified product, the exponential growth phase of PCR product can be detected and used to determine the initial template concentration (Heid et al., 1996, and Gibson et al., 1996).
  • the amplification of an endogenous control can be performed to standardise the amount of sample RNA added to a reaction.
  • the control of choice is the 18S ribosomal RNA. Since reporter dyes with differing emission spectra are available, the target and the endogenous control can be independently quantified in the same tube if probes labelled with different dyes are used.
  • RNAs used for expression quantification are listed in Table 1 along with their purchasers.
  • RNA final concentration in the reaction mix was 200ng/ ⁇ L. Reverse transcription was made with 2.5 ⁇ M of random hexamers.
  • the expected length of the PCR product was 80bp.
  • Quantification experiments were performed on 50 ng of reverse transcribed RNA from each sample. Each determination was done in triplicate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon l'invention, les réactifs permettant de réguler une enzyme humaine du type dipeptidyl-peptidase IV et les réactifs se liant à des produits géniques de l'enzyme humaine dipeptidyl-peptidase IV peuvent jouer un rôle dans la prévention, l'amélioration ou la correction de dysfonctionnements ou de maladies, notamment, mais pas exclusivement, les tumeurs et les troubles des systèmes nerveux périphérique et central, tels que la douleur et les troubles neurodégénératifs.
PCT/EP2001/007730 2000-07-10 2001-07-06 Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv WO2002004610A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001269123A AU2001269123A1 (en) 2000-07-10 2001-07-06 Regulation of human dipeptidyl-peptidase iv-like enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21707500P 2000-07-10 2000-07-10
US60/217,075 2000-07-10

Publications (2)

Publication Number Publication Date
WO2002004610A2 true WO2002004610A2 (fr) 2002-01-17
WO2002004610A3 WO2002004610A3 (fr) 2002-07-11

Family

ID=22809580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007730 WO2002004610A2 (fr) 2000-07-10 2001-07-06 Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv

Country Status (2)

Country Link
AU (1) AU2001269123A1 (fr)
WO (1) WO2002004610A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092127A1 (fr) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Therapie a base d'anticorps monoclonaux anti-cd26 contre des affections en lien avec des cellules exprimant le cd26
WO2003033524A2 (fr) 2001-10-12 2003-04-24 Probiodrug Ag Peptidyl-cetones comme inhibiteurs de molecules dipeptidyl peptidase de type iv
WO2004017989A1 (fr) 2002-08-09 2004-03-04 Prosidion Ltd. Procedes pour ameliorer la signalisation des ilots dans le cas du diabete sucre et procedes pour prevenir ce dernier
WO2004098625A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Utilisation d'effecteurs de glutaminyl- et de glutamate-cyclases
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
US7625939B2 (en) 2005-11-14 2009-12-01 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
EP2206496A1 (fr) 2003-05-05 2010-07-14 Probiodrug AG Utilisation médicale d'inhibiteurs de glutaminyl- et de glutamate cyclases
EP2289498A1 (fr) 2003-10-15 2011-03-02 Probiodrug AG Utilisation des inhibiteurs de la glutaminyl cyclase
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2338490A2 (fr) 2003-11-03 2011-06-29 Probiodrug AG Combinaisons utiles pour le traitement de désordres neuronales
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1942898E (pt) 2005-09-14 2011-12-20 Takeda Pharmaceutical Inibidores da dipeptidilpeptidase para o tratamento da diabetes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM D F ET AL: "Proline specific peptidases" BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM,, NL, vol. 1343, no. 2, 5 December 1997 (1997-12-05), pages 160-186, XP004278373 ISSN: 0167-4838 *
DATABASE EMBL [Online] ID: AB040925, 23 May 2000 (2000-05-23) OHARA O., NAGASE T., KIKUNO R.: "Homo sapiens mRNA for KIAA1492 protein, partial cds." XP002193822 *
DATABASE EMBL [Online] ID: HS809117, 25 May 1995 (1995-05-25) HILLIER L. ET AL.: "yg99h11.r1 Soares infant brain 1NIB Homo sapiens cDNA clone IMAGE:41862 5'" XP002193821 *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XVII. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO" DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 7, no. 6, 2000, pages 143-150, XP000943428 ISSN: 1340-2838 *
YOKOTANI N ET AL: "NON-CONSERVATION OF A CATALYTIC RESIDUE IN A DIPEPTIDYL AMINOPEPTIDASE IV-RELATED PROTEIN ENCODED BY A GENE ON HUMAN CHROMOSOME 7" HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 2, no. 7, July 1993 (1993-07), pages 1037-1039, XP001026522 ISSN: 0964-6906 -& DATABASE EMBL [Online] AC: P42658, 1 November 1995 (1995-11-01) YOKOTANI,N., DOI,K., WENTHOLD,R.J., WADA,K.,: "DIPEPTIDYL PEPTIDASE IV LIKE PROTEIN (DIPEPTIDYL AMINOPEPTIDASE- RELATED PROTEIN)(DIPEPTIDYLPEPTIDASE VI) (DPPX)." XP002193823 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092127A1 (fr) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Therapie a base d'anticorps monoclonaux anti-cd26 contre des affections en lien avec des cellules exprimant le cd26
US7198788B2 (en) 2001-05-11 2007-04-03 Board Of Regents, The University Of Texas System Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26.
US7658923B2 (en) 2001-05-11 2010-02-09 Board Of Regents, The University Of Texas System Anti-CD26 monoclonal antibodies as therapy for diseases associated with cells expressing CD26
WO2003033524A2 (fr) 2001-10-12 2003-04-24 Probiodrug Ag Peptidyl-cetones comme inhibiteurs de molecules dipeptidyl peptidase de type iv
WO2004017989A1 (fr) 2002-08-09 2004-03-04 Prosidion Ltd. Procedes pour ameliorer la signalisation des ilots dans le cas du diabete sucre et procedes pour prevenir ce dernier
DE202004021723U1 (de) 2003-05-05 2010-07-15 Probiodrug Ag Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen
WO2004098625A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Utilisation d'effecteurs de glutaminyl- et de glutamate-cyclases
EP2206496A1 (fr) 2003-05-05 2010-07-14 Probiodrug AG Utilisation médicale d'inhibiteurs de glutaminyl- et de glutamate cyclases
EP2289498A1 (fr) 2003-10-15 2011-03-02 Probiodrug AG Utilisation des inhibiteurs de la glutaminyl cyclase
EP2338490A2 (fr) 2003-11-03 2011-06-29 Probiodrug AG Combinaisons utiles pour le traitement de désordres neuronales
WO2005075436A2 (fr) 2004-02-05 2005-08-18 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7625939B2 (en) 2005-11-14 2009-12-01 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor

Also Published As

Publication number Publication date
WO2002004610A3 (fr) 2002-07-11
AU2001269123A1 (en) 2002-01-21

Similar Documents

Publication Publication Date Title
WO2002059621A2 (fr) Regulation de transthyretine afin de traiter l'obesite
WO2002004610A2 (fr) Regulation d'une enzyme humaine du type dipeptidyl-peptidase iv
US20030171324A1 (en) Regulation of human desc1-like serine protease
US20030003488A1 (en) Regulation of human mitochondrial deformylase
US6593099B2 (en) Regulation of human S-acyl fatty acid synthase thioesterase-like enzyme
US6821745B2 (en) Regulation of human pyroglutamyl peptidase-like enzyme
US7060456B2 (en) Regulation of human protein phosphatase IIc-like enzyme
US20040175815A1 (en) Regulation of human p78-like serube/threonine kinase
US20030175941A1 (en) Regulation of human serine racemase enzyme
WO2002006454A2 (fr) Regulation d'une enzyme humaine de type carboxylesterase
WO2002042435A2 (fr) Regulation de la tyrosine phosphatase humaine
WO2002030969A2 (fr) Regulation une enzyme humaine de type carboxyesterase
WO2001072833A2 (fr) Regulation de recepteur humain de type ephrine
WO2001090318A2 (fr) Regulation de l'enzyme similaire a la polyamine oxydase humaine
US20040029247A1 (en) Regulation of human adenylate cyclase, type iv
US20030049670A1 (en) Regulation of human leucine aminopeptidase-like enzyme
WO2002024884A2 (fr) Regulation de l'enzyme analogue a la serine palmitoyltransferase humaine
EP1272646A2 (fr) Regulation de serine racemase humaine
WO2002000703A2 (fr) Regulation de l'enzyme de type glutamyl-arnt (gln) amido-transferase humaine
WO2001068879A2 (fr) Regulation de la 1-aminocyclopropane-carboxylate synthase humaine
WO2002046403A2 (fr) Regulation de la proteine humaine du type 'patched'
WO2001072955A2 (fr) Regulation de la proteine humaine apparentee a nedd1
WO2002044351A2 (fr) Regulation de la coa ligase humaine d'acides gras
WO2001073017A2 (fr) Regulation de la proteine humaine apparentee au facteur d'adp-ribosylation
WO2001075075A2 (fr) Regulation d'une enzyme humaine de type tyrosine phosphatase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP